摘要
目的探讨依达拉奉联合尿激酶(UK)静脉溶栓对急性脑梗死患者的疗效、安全性以及对机体氧化应激水平的影响。方法120例急性脑梗死患者随机分为对照组60例与观察组60例;对照采取尿激酶溶栓治疗,观察组给予依达拉奉联合尿激酶溶栓治疗;比较2组神经功能缺损(NIHSS)评分、日常生活(Barthel)指数、mRS评分,观察急性脑梗死溶栓效果,评价2组临床疗效和症状性颅内出血(SICH)发生率,并比较2组治疗前后血清氧化应激指标GSH-Px和ROS水平。结果治疗24h与7d后对照组与观察组NHISS评分和Barthel评分无明显差异(P>0.05);治疗7d与14d后对照组与观察组mRS评分无明显差异(P>0.05);治疗24h后对照组与观察组血管再通率无明显差异(P>0.05);治疗28 d后观察组总有效率为85.00%,高于对照组的78.33%(P>0.05);观察组SICH发生率为1.67%,低于对照组的6.67%(P>0.05);治疗后2组GSH-Px水平均显著升高(P<0.05),而ROS均明显下降(P<0.05);治疗后观察组GSH-Px水平显著高于对照组(P<0.05),而ROS显著低于对照组(P<0.05)。结论依达拉奉联合UK治疗急性脑梗死(发病6~12 h)能取得良好疗效,能更好地改善机体氧化应激水平,较单用尿激酶溶栓的安全性更高。
Objective To investigate the efficacy and safety of edaravone,urokinase(UK)intravenous thrombolysis in patients with mild acute cerebral infarction and their effect on oxidative stress levels.Methods A total of 120 patients with acute cerebral infarction were randomly divided into the observation group and the control group.There were 60 patients in each group.Patients in the control group underwent thrombolytic therapy with urokinase,and those in the observation group received edaravone combined with thrombolysis with urokinase.The neurological deficit(NIHSS)score,barthel index,mRS score,and thrombolysis of acute myocardial infarction were compared between the two groups.Clinical efficacy and symptomatic intracranial hemorrhage(SICH)were evaluated in two groups.Moreover,the parametrs of oxidative stress,GSH-Px and ROS levels were also measured and compared between two groups.Results There were no significant differences in the scores of NHISS and Barthel between24h and 7d after treatment(P>0.05).At 7th and 14th d after treatment,there was no significant difference in mRS scores between the two groups(P>0.05).There was no significant difference in revascularization between two groups at 24th h after treatment(P>0.05).At 28th d after treatment,the total effective rate in the observation group was 85.00%,which was higher than 78.33%in the control group,but there was no significant difference(P>0.05).The incidence of SICH in the observation group was 1.67%,which was lower than6.67%in the control group,but there was no significant difference(P>0.05).After treatment,GSH-Px level in two groups increased significantly and ROS declined dramatically when compared to pre-treatment(P<0.05).GSH-Px level in the observation group was much higher than that in the control group and ROS level in the observation group was obviously less than that in the control group(P<0.05).Conclusion Edaravone combined urokinase(UK)intravenous thrombolysis could ·398· Stroke and Nervous Diseases,Aug 2019,Vol.26,No.4 achieve better outcomes in the treatment of acute cerebral infarction(6~12 h),reduce the oxidative stress level and be safer than urokinase alone.
作者
刘暖林
石波
陈碧霞
Liu Nuanlin;Shi Bo;Chen Bixia(Dongguan Liaobu Hospital,Dongguan 523400)
出处
《卒中与神经疾病》
2019年第4期398-401,共4页
Stroke and Nervous Diseases
关键词
脑梗死
静脉溶栓
依达拉奉
尿激酶
氧化应激
Cerebral infarction
Intravenous thrombolysis
Edaravone
Urokinase Oxidative stress
